Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Depreciation & Amortization (CF) (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 55.17% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.2 million, a 43.59% increase, with the full-year FY2025 number at $11.2 million, up 43.59% from a year prior.
  • Depreciation & Amortization (CF) was $2.9 million for Q4 2025 at Denali Therapeutics, down from $2.9 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $10.0 million in Q1 2023 to a low of $1.8 million in Q3 2024.
  • A 5-year average of $2.7 million and a median of $2.2 million in 2021 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 383.26% in 2023, then crashed 78.48% in 2024.
  • Denali Therapeutics' Depreciation & Amortization (CF) stood at $2.1 million in 2021, then skyrocketed by 96.18% to $4.1 million in 2022, then crashed by 47.01% to $2.2 million in 2023, then dropped by 14.65% to $1.9 million in 2024, then surged by 55.17% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Depreciation & Amortization (CF) are $2.9 million (Q4 2025), $2.9 million (Q3 2025), and $3.0 million (Q2 2025).